Renal cell carcinoma bone metastases: Clinical advances

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 2, 2010, Pages 75-83

  Sahi, Chakshu ^a   Knox, Jennifer J ^a   Clemons, Mark ^a   Joshua, Anthony M ^a   Broom, Reuben ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

bisphosphonates; bone metastases; bone pain scales; renal cell carcinoma; targeted therapy; urinary N telopeptide

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CD135 ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR; DASATINIB; DENOSUMAB; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; ODANACATIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; KIDNEY CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE;

EID: 77955628611     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009358417     Document Type: Review

References (40)

1. Badalian, G., Derecskei, K., Szendroi, A., Szendroi, M. and Timar, J. ( 2007) EGRF and VEGFR 2 protein expressions in bone metastases of clear cell renal cancer. Anticancer Res 27: 889-894.
2. Broom, R., Simmons, C., Clemons, M. and Cole, D. ( 2007) The role of urinary n-telopeptides in evaluating the palliative benefit of bisphosphonates in metastatic breast cancer. Prog Pall Care 15: 1-5.
3. Broom, R., Du, H., Clemons, M., Eton, D., Dranitsaris, G., Simmons, C. et al. (2009) Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy - Bone Pain. J Pain Symptom Manage 38: 244-257.
4. Brown, E., Thomson, C.S., Ellis, S.P., Gutcher, S.A., Purohit, O.P. and Coleman, R.E. ( 2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89: 2031-2037.
5. Bukowski, R.M., Eisen, T., Szczylik, C., Stadler, W.M., Simantov, R., Shan, M. et al. (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25(18S): abstr 5023.
6. Clamp, A., Danson, S., Nguyen, H., Cole, D. and Clemons, M. ( 2004) Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 5: 607-616.
7. Coleman, R.E., Major, P., Lipton, A., Brown, J.E., Lee, K.A., Smith, M. et al. (2005) Predictive value of bone resporption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925-4935.
8. Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M. et al. (2007 a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
9. Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C. et al. (2007 b) Bevacizumab plus interferon alpha-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111.
10. Fleisch, H. ( 2002) The role of bisphosphonates in breast cancer: development of bisphosphonates. Breast Cancer Res 4: 30-34.
11. Fyfe, G., Fisher, R.I., Rosenberg, S.A., Sznol, M., Parkinson, D.R. and Louie, A.C. ( 1995) Results of treatment of 255 pateints with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696.
12. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A. et al. (2007) Temsirolimus, interferon-alpha or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
13. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. ( 2009) Cancer statistics. CA Cancer J Clin 59: 225-249.
14. Jensen, A.B., Olmeo, N., Wynne, C., Ramirez, G., Lebrecht, A., Mehta, A. et al. (2008) Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial. J Clin Oncol 26(15S): abstr 1023.
15. Kneissel, M., Luong-Nguyen, N.H., Baptist, M., Cortesi, R., Zumstein-Mecker, S., Kossida, S. et al. (2004) Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 35: 1144-1156.
16. Kominsky, S.L., Doucet, M., Brady, K. and Weber, K.L. ( 2007) TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. J Bone Miner Res 22: 37-44.
17. Kominsky, S.L., Abdelmagid, S.M., Doucet, M., Brady, K. and Weber, K.L. ( 2008) Macrophage inflammatory protein-1 delta: a novel osteoclast stimulating factor secreted by renal cell carcinoma bone metastasis. Cancer Res 68: 1261-1266.
18. Lipton, A., Colombo-Berra, A., Bukowski, R.M., Rosen, L., Zheng, M. and Urbanowitz, G. ( 2004) Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10: 6397S-6403S.
19. McLaughlin, J.K. and Lipworth, L. ( 2000) Epidemiological aspects of renal cell cancer. Semin Oncol 27: 115-123.
20. Motzer, R.J., Bander, N.H. and Nanus, D.M. ( 1996) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. N Engl J Med 335: 865-875.
21. Motzer, R.J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A. and Ferrara, J. ( 1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540.
22. Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O. et al. (2007) Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
23. Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S. et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double blinded, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
24. Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Oudard, S. et al. (2009) Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
25. Murray, L.J., Abrams, T.J., Long, K.R., Ngai, T.J., Olson, L.M., Hong, W. et al. (2003) SU 11248 inhibits tumor growth and CSF-1R dependant osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metast 20: 757-766.
26. Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K. et al. (1998) RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253: 395-400.
27. Negrier, S., Escudier, B., Lasset, C., Douillard, J.Y., Savary, J., Chevreau, C. et al. (1998) Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272-1278.
28. Ooi, W.S., Popovic, S., Kalina, M., Kahn, H., Singh, G., Gainford, M.C. et al. (2007) Mechanisms of bone metastasis (BM) growth in patients with metastatic breast cancer (MBC): an exploratory study. J Clin Oncol 25(18S): abstr 1102.
29. Patil, S., Figlin, R.A., Hutson, T.E., Michaelson, M.D., Negrier, S., Kim, S.T. et al. (2009) Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15S): abstr 5042.
30. Riechelmann, R.P., Chin, S., Wang, L., Tannock, I.F., Berthold, D.R., Moore, M.J. et al. (2008) Sorafenib for metastatic renal cancer: the Princess Margaret Experience. Am J Clin Oncol 31: 182-187.
31. Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Ou, S.S. et al. (2008) Bevacizumab plus interferon alpha compared with interferon alpha monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26: 5422-5428.
32. Rosen, L.S., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M. et al. (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumor Study Group. J Clin Oncol 21: 3150-3157.
33. Sahi, C., Knox, J.J., Hinder, V., Deva, S., Cole, D., Clemons, M. et al. (2009) The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma. J Clin Oncol 27(suppl): abstr e16145.
34. Staehler, M., Haseke, N., Stadler, T., Steif, C.G. and Wilkowski, R. ( 2009) Effectivity of simultaneous radiation therapy and multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. Proc Am Soc Clin Oncol, Genitourinary Cancer Symposium [abstract 334].
35. Tunn, U., Stenzl, A., Kindler, M., Strauss, A., Miller, K., Reubel, A. et al. (2009) The effect of zoledronic acid on bone metastasis in patients suffering from renal cell cancer (RCC): a German prospective single-arm clinical trial. J Clin Oncol 27(15S): abstr 5107.
36. Weber, K., Doucet, M. and Kominsky, S. ( 2007) Renal cell carcinoma bone metastasis - elucidating the molecular targets. Cancer Metastasis Rev 26: 691-704.
37. Wildes, T.M., Procknow, E., Gao, F., Dipersio, J.F. and Vij, R. (2009) Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk Lymphoma 50: 137-140.
38. Wittrant, Y., Theoleyre, S., Chipoy, C., Padrines, M., Blanchard, F., Heymann, D. et al. (2004) RANKL/ RANK/OPG: new therapeutic targets in bone tumors and associated osteolysis. Biochim Biophys Acta 1704: 49-57.
39. Wrobel, C.N., Debnath, J., Lin, E., Beausoleil, S., Roussel, M.F. and Brugge, J.S. ( 2004) Autocrine CSF-1R activation promotes Src-dependant disruption of mammary epithelial architecture. J Cell Biol 165: 263-273.
40. Zekri, J., Ahmed, N., Coleman, R.E. and Hancock, B.W. ( 2001) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19: 379-382.